CTNM
HealthcareContineum Therapeutics, Inc. Class A Common Stock · Biotechnology · $520M
What is Contineum Therapeutics, Inc. Class A Common Stock?
Contineum Therapeutics is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing oral small molecule therapies for serious neurological and inflammatory diseases with limited existing treatment options.
Contineum discovers and develops oral small molecule drugs targeting neuroscience, inflammation, and immunology. Its pipeline centers on receptor-targeting compounds designed to address conditions such as idiopathic pulmonary fibrosis, multiple sclerosis, and depression. The company generates no product revenue at this stage — it operates as a research and development organization funded through capital raises while advancing its clinical programs toward potential regulatory milestones.
The company was incorporated in 2009 and is headquartered in San Diego, California.
- PIPE-791 — LPA1R inhibitor targeting idiopathic pulmonary fibrosis and progressive MS
- PIPE-307 — M1 receptor inhibitor for depression and relapsing-remitting MS
- CTX-343 — peripherally-restricted LPA1R antagonist in development
Is CTNM a Good Stock to Buy?
UQS Score rates CTNM as Poor overall, reflecting the early-stage nature and inherent uncertainties of a pre-revenue clinical biopharmaceutical company.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's balance sheet and near-term financial exposure are managed more carefully than many peers at this stage. Valuation is rated Elevated, which warrants attention given the absence of commercial revenue.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no approved products, no recurring revenue, and a pipeline still in clinical development.
Sign up to see the full pillar breakdown and detailed financial metrics behind CTNM's UQS Score. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CTNM pay dividends?
No — Contineum Therapeutics, Inc. Class A Common Stock does not currently pay a dividend.
Contineum Therapeutics does not pay a dividend. As a pre-revenue clinical-stage company, available capital is directed entirely toward research, clinical trials, and pipeline advancement. Income-focused investors should note that dividend distributions are unlikely until the company reaches commercial-stage operations.
When does CTNM report earnings?
Contineum Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a clinical-stage company, quarterly reports focus primarily on cash runway, operating expenses, and pipeline progress rather than product revenue or profitability. Key updates to watch include clinical trial readouts and any partnership or financing announcements.
For the most recent quarter's results and pipeline updates, visit Contineum Therapeutics' investor relations page directly.
CTNM Price History
-15.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Contineum Therapeutics, Inc. Class A Common Stock?
Based on Contineum Therapeutics, Inc. Class A Common Stock's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
CTNM Long-term Outlook
The fundamental outlook for CTNM is shaped by clinical execution risk rather than commercial momentum. With Growth and Quality both rated Weak, near-term value creation depends heavily on clinical trial outcomes for its lead assets. The Good Risk rating suggests the company has managed its financial position with some discipline, but the Elevated Valuation label indicates the market may already be pricing in optimistic pipeline scenarios.
Growth drivers
- Potential clinical trial milestones for PIPE-791 in pulmonary fibrosis and progressive MS
- Advancement of PIPE-307 through development for depression and relapsing-remitting MS
- Possible partnership or licensing deals that could validate the pipeline
Key risks
- Clinical trial failure — a common and significant risk for pre-revenue biotechs
- Elevated valuation relative to the current stage of development
- Ongoing cash burn with no product revenue to offset operating expenses
CTNM vs Peers
Contineum operates in a competitive clinical-stage landscape alongside other small-cap biotechs pursuing novel therapeutic mechanisms.
MiMedx focuses on regenerative medicine and tissue products, giving it a commercial revenue base that distinguishes it from purely clinical-stage peers like Contineum.
DBV Technologies develops epicutaneous immunotherapy patches, competing in the immunology space with a different delivery mechanism than Contineum's oral small molecule approach.
Lexeo pursues gene therapy programs, representing a fundamentally different modality from Contineum's small molecule strategy despite overlapping in rare and neurological disease focus areas.
Frequently Asked Questions
What does Contineum Therapeutics do?
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies for neurological, inflammatory, and immunological diseases. Its pipeline targets conditions including idiopathic pulmonary fibrosis, multiple sclerosis, and depression — all areas with significant unmet medical need.
Does CTNM pay dividends?
No, CTNM does not pay a dividend. The company is pre-revenue and reinvests all available capital into its clinical programs. Dividends are not expected until the company reaches a commercial stage, which remains dependent on successful clinical and regulatory outcomes.
When does CTNM report earnings?
Contineum Therapeutics reports on a quarterly cadence. Because the company is pre-revenue, reports focus on operating expenses, cash position, and pipeline progress. For exact dates, check the investor relations section of the company's official website.
Is CTNM a good stock to buy?
UQS Score rates CTNM as Poor overall, driven by Weak scores across Quality, Moat, and Growth pillars. The Risk pillar is rated Good, which is a relative positive. Investors should weigh the clinical-stage risks carefully. See the full UQS breakdown for a complete picture.
Is CTNM overvalued?
The UQS Valuation pillar for CTNM is rated Elevated, suggesting the current market price may reflect optimistic assumptions about pipeline success. For a pre-revenue biotech, valuation is inherently speculative and tied closely to clinical trial outcomes.
How does CTNM compare to its competitors?
Compared to peers like MiMedx, DBV Technologies, and Lexeo Therapeutics, Contineum is distinguished by its oral small molecule focus across neuroscience and inflammation. Unlike MiMedx, it has no commercial products yet. Its approach differs from Lexeo's gene therapy and DBV's patch-based delivery.
What is CTNM's market cap bracket?
CTNM is classified as a small-cap stock. This places it among smaller publicly traded companies, which typically carry higher volatility and liquidity risk compared to mid-cap or large-cap peers, particularly relevant for a pre-revenue clinical-stage company.
Who founded Contineum Therapeutics?
The company was originally incorporated in 2009 under the name Pipeline Therapeutics, Inc. and rebranded to Contineum Therapeutics in November 2023. Detailed founding information is publicly available through the company's SEC filings and official communications.
Is CTNM a long-term quality investment?
As a long-term quality indicator, UQS rates CTNM as Poor — reflecting weak fundamentals across most pillars at this stage. Long-term potential depends entirely on clinical success. The full UQS pillar breakdown, available to Pro members, provides a deeper view of the quality trajectory.
What is the main competitive advantage of Contineum Therapeutics?
Contineum's differentiation lies in its focus on brain-penetrant, oral small molecules — a delivery format that can offer advantages over injectable biologics in neurological conditions. However, the Moat pillar is rated Weak, reflecting that no durable commercial advantage has yet been established.
Unlock Full CTNM Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access detailed financial metrics and trend data for CTNM
- ✓Compare CTNM side-by-side with clinical-stage biotech peers
- ✓Track pipeline risk indicators and balance sheet health over time
- ✓Get the full analyst-grade view available exclusively to Pro members
Pro Analysis
CTNM — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 10, 2026 | 13.3 | 0.0 | 9.0 | 0.3 | 73.3 | 0.0 | +0.1 |
| May 9, 2026 | 13.2 | 0.0 | 9.0 | 0.0 | 73.3 | 0.0 | +1.1 |
| Apr 2, 2026 | 12.1 | 0.0 | 9.0 | 0.3 | 65.3 | 0.0 | — |
CTNM — Pillar Breakdown
Quality
— 0.0/100 (25%)Contineum Therapeutics, Inc. Class A Common Stock currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.3/100 (20%)Contineum Therapeutics, Inc. Class A Common Stock faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 73.3/100 (15%)Contineum Therapeutics, Inc. Class A Common Stock maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Contineum Therapeutics, Inc. Class A Common Stock appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 9/100 (25%)Contineum Therapeutics, Inc. Class A Common Stock operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CTNM.
Score Composition
Financial Data
More Stock Analysis
How is the CTNM UQS Score Calculated?
The UQS (Unified Quality Score) for Contineum Therapeutics, Inc. Class A Common Stock is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Contineum Therapeutics, Inc. Class A Common Stock's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Contineum Therapeutics, Inc. Class A Common Stock is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.